What are the limitations of the iss myeloma?

While the iss myeloma is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the iss myeloma to ensure safe bedside use and optimal diagnostic accuracy.

How does the iss myeloma compare to other hematology scores?

The iss myeloma is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the iss myeloma free to use?

Yes. OpiCalc provides the iss myeloma completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

ISS (Myeloma)

ISS (International Staging System): Standard biochemical staging for MM. Uses Serum Beta-2-Microglobulin and Albumin.

Beta-2 Microglobulin (mg/L)

Serum Albumin (g/dL)

Clinical Stage (ISS)

—

Enter lab values to determine stage.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Baseline staging of patients with newly diagnosed Multiple Myeloma.

Predicting overall survival (OS) based on serum protein biomarkers.

Standardizing patient cohorts for clinical trials.

Patient Population

Adult patients with symptomatic Multiple Myeloma.

When Not to Rely on This Score Alone

Smoldering Myeloma / MGUS — these conditions use different progression risk models (e.g., 20/2/20 criteria).

Relapsed Myeloma — ISS is intended for baseline use; its utility in relapsed disease is less robust.

Modern Risk Assessment — ISS is purely biochemical. For most patients, the Revised ISS (R-ISS) should be used to incorporate cytogenetics (FISH) and LDH.

Section 2

Formula & Logic

Criteria

Stage	Definition
I	Serum β2-microglobulin < 3.5 mg/L AND Serum Albumin ≥ 3.5 g/dL
III	Serum β2-microglobulin ≥ 5.5 mg/L
II	Neither Stage I nor Stage III

Outcomes (Original Era)

Stage	Median Survival (Months)
I	62
II	44
III	29

Section 3

Pearls/Pitfalls

The Power of Beta-2

Serum Beta-2 microglobulin is a direct marker of tumor burden and is influenced significantly by renal function. Since renal impairment (the "R" in CRAB) is a hallmark of aggressive myeloma, Beta-2 is a particularly potent predictor.

Section 4

Evidence Appraisal

Primary Score

International staging system for multiple myeloma.

Greipp PR et al. • Journal of Clinical Oncology. 2005;23(15):3412-20.

View Source

Section 5

Literature

Development

Developed by the International Myeloma Working Group (IMWG) analyzing data from over 10,000 patients. It replaced the more complex Durie-Salmon system due to its simplicity and reproducibility.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Baseline staging of patients with newly diagnosed Multiple Myeloma.

Predicting overall survival (OS) based on serum protein biomarkers.

Standardizing patient cohorts for clinical trials.

Patient Population

Adult patients with symptomatic Multiple Myeloma.

When Not to Rely on This Score Alone

Smoldering Myeloma / MGUS — these conditions use different progression risk models (e.g., 20/2/20 criteria).

Relapsed Myeloma — ISS is intended for baseline use; its utility in relapsed disease is less robust.

Modern Risk Assessment — ISS is purely biochemical. For most patients, the Revised ISS (R-ISS) should be used to incorporate cytogenetics (FISH) and LDH.

Section 2

Formula & Logic

Criteria

Stage	Definition
I	Serum β2-microglobulin < 3.5 mg/L AND Serum Albumin ≥ 3.5 g/dL
III	Serum β2-microglobulin ≥ 5.5 mg/L
II	Neither Stage I nor Stage III

Outcomes (Original Era)

Stage	Median Survival (Months)
I	62
II	44
III	29

Section 3

Pearls/Pitfalls

The Power of Beta-2

Section 4

Evidence Appraisal

Primary Score

International staging system for multiple myeloma.

Greipp PR et al. • Journal of Clinical Oncology. 2005;23(15):3412-20.

View Source

Section 5

Literature

Development

Developed by the International Myeloma Working Group (IMWG) analyzing data from over 10,000 patients. It replaced the more complex Durie-Salmon system due to its simplicity and reproducibility.

Last Comprehensive Review: 2026

Related Hematology Tools

FLIPI-2

MIPI

aaIPI

IPSID / Lugano Classification

Deauville Score Interpreter

CLL-IPI

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

Have feedback about this calculator?Let us know.

ISS (Myeloma)

ISS (International Staging System): Standard biochemical staging for MM. Uses Serum Beta-2-Microglobulin and Albumin.

Beta-2 Microglobulin (mg/L)

Serum Albumin (g/dL)

Clinical Stage (ISS)

—

Enter lab values to determine stage.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Baseline staging of patients with newly diagnosed Multiple Myeloma.

Predicting overall survival (OS) based on serum protein biomarkers.

Standardizing patient cohorts for clinical trials.

Patient Population

Adult patients with symptomatic Multiple Myeloma.

When Not to Rely on This Score Alone

Smoldering Myeloma / MGUS — these conditions use different progression risk models (e.g., 20/2/20 criteria).

Relapsed Myeloma — ISS is intended for baseline use; its utility in relapsed disease is less robust.

Modern Risk Assessment — ISS is purely biochemical. For most patients, the Revised ISS (R-ISS) should be used to incorporate cytogenetics (FISH) and LDH.

Section 2

Formula & Logic

Criteria

Stage	Definition
I	Serum β2-microglobulin < 3.5 mg/L AND Serum Albumin ≥ 3.5 g/dL
III	Serum β2-microglobulin ≥ 5.5 mg/L
II	Neither Stage I nor Stage III

Outcomes (Original Era)

Stage	Median Survival (Months)
I	62
II	44
III	29

Section 3

Pearls/Pitfalls

The Power of Beta-2

Section 4

Evidence Appraisal

Primary Score

International staging system for multiple myeloma.

Greipp PR et al. • Journal of Clinical Oncology. 2005;23(15):3412-20.

View Source

Section 5

Literature

Development

Developed by the International Myeloma Working Group (IMWG) analyzing data from over 10,000 patients. It replaced the more complex Durie-Salmon system due to its simplicity and reproducibility.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Baseline staging of patients with newly diagnosed Multiple Myeloma.

Predicting overall survival (OS) based on serum protein biomarkers.

Standardizing patient cohorts for clinical trials.

Patient Population

Adult patients with symptomatic Multiple Myeloma.

When Not to Rely on This Score Alone

Smoldering Myeloma / MGUS — these conditions use different progression risk models (e.g., 20/2/20 criteria).

Relapsed Myeloma — ISS is intended for baseline use; its utility in relapsed disease is less robust.

Modern Risk Assessment — ISS is purely biochemical. For most patients, the Revised ISS (R-ISS) should be used to incorporate cytogenetics (FISH) and LDH.

Section 2

Formula & Logic

Criteria

Stage	Definition
I	Serum β2-microglobulin < 3.5 mg/L AND Serum Albumin ≥ 3.5 g/dL
III	Serum β2-microglobulin ≥ 5.5 mg/L
II	Neither Stage I nor Stage III

Outcomes (Original Era)

Stage	Median Survival (Months)
I	62
II	44
III	29

Section 3

Pearls/Pitfalls

The Power of Beta-2

Section 4

Evidence Appraisal

Primary Score

International staging system for multiple myeloma.

Greipp PR et al. • Journal of Clinical Oncology. 2005;23(15):3412-20.

View Source

Section 5

Literature

Development

Developed by the International Myeloma Working Group (IMWG) analyzing data from over 10,000 patients. It replaced the more complex Durie-Salmon system due to its simplicity and reproducibility.

Last Comprehensive Review: 2026

Related Hematology Tools

FLIPI-2

MIPI

aaIPI

IPSID / Lugano Classification

Deauville Score Interpreter

CLL-IPI

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

Have feedback about this calculator?Let us know.